UBS Maintains Neutral on McCormick & Co, Lowers Price Target to $48
UBS analyst Peter Grom maintains McCormick & Co (NYSE:MKC) with a Neutral and lowers the price target from $52 to $48.
Stocks · News reference
McCormick Analysts Slash Their Forecasts After Q3 Results
McCormick beats Q3 estimates with $2.02B sales and 86-cent EPS, reaffirms FY26 outlook; analysts cut price targets to $48.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cooper Companies Director Kurzius Buys $549,300 in Shares. Is the Eye Care Stock About to Rally?
Lawrence Erik Kurzius, a Director at Cooper Companies, purchased 10,000 shares worth $549,300 at $54.93 per share on September 16, 2026, increasing his total holdings to 31,099 shares. The insider buy signals confidence in the company's recovery prospects following a 16% stock decline over the past year. The article notes that insider purchases typically predict higher share prices within 30 days and suggest management believes in the company's long-term growth, particularly after deciding to retain its surgical unit rather than divest it.
BNP Paribas Maintains Outperform on McCormick & Co, Lowers Price Target to $65
BNP Paribas analyst Max Gumport maintains McCormick & Co (NYSE:MKC) with a Outperform and lowers the price target from $75 to $65.